<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013389</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0702PLF</org_study_id>
    <secondary_id>ACTRN12609000527268</secondary_id>
    <secondary_id>EudraCT Number: 2009-012672-27</secondary_id>
    <nct_id>NCT01013389</nct_id>
  </id_info>
  <brief_title>Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion</brief_title>
  <acronym>APPRAISET1</acronym>
  <official_title>A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark)ABX Synthetic Bone Substitute With INFUSE (Registrered Trademark) in Patients Requiring Posterolateral Instrumented Lumbar Fusion With Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apatech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical trial is to evaluate the success rates of Actifuse ABX&#xD;
      and INFUSE in achieving bone fusion.&#xD;
&#xD;
      The secondary objective of this clinical trial is to assess clinical outcome measurements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion, defined as evidence of bridging trabecular bone present at 1 year as assessed by CT scan as well as a determination of no motion as assessed by plain radiographs.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement clinical outcomes measurements compared to pre-opscores: pain/Disability as measured by Oswestry Lower Back Pain Questionnaire, quality of Life as measured by Short Form Health Survey (SF36), and neurological status</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Actifuse ABX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Actifuse ABX bone substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INFUSE, plus master granules (MGG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Actifuse ABX</intervention_name>
    <description>bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion</description>
    <arm_group_label>Actifuse ABX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>INFUSE, plus master granules (MGG)</intervention_name>
    <description>bone substitute in posterolateral instrumented lumbar fusion with interbody fusion</description>
    <arm_group_label>INFUSE, plus master granules (MGG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has degenerative disc disease of the lumbar spine as indicated by back pain of&#xD;
             discogenic/degenerative origin, with or without leg pain, and has one or more of the&#xD;
             following conditions as documented by plain X-rays, CT scan or MRI scan:&#xD;
&#xD;
               -  Modic changes.&#xD;
&#xD;
               -  High intensity changes in the annulus.&#xD;
&#xD;
               -  Loss of disc height.&#xD;
&#xD;
               -  Decreased hydration of the disc.&#xD;
&#xD;
               -  Canal stenosis with or without spondylotic slip.&#xD;
&#xD;
               -  Gross facet joint changes requiring fusion for treatment.&#xD;
&#xD;
               -  Have documented annular pathology by other means. (e.g., with discography).&#xD;
&#xD;
          -  Has a preoperative Oswestry Back Disability Score of 30 or more.&#xD;
&#xD;
          -  Aged 18 to 75 years and skeletally mature at time of surgery.&#xD;
&#xD;
          -  Has not responded to non-operative treatment (e.g., bed rest, physical therapy,&#xD;
             medications and/or spinal injections) for a period of six months.&#xD;
&#xD;
          -  If of childbearing potential, patient is non-pregnant, non-nursing and agrees not to&#xD;
             become pregnant for one year following surgery.&#xD;
&#xD;
          -  Is willing to and able to comply with the study plan and able to understand and sign&#xD;
             the Patient Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has had previous failed attempts at fusion surgery at the involved level(s).&#xD;
&#xD;
          -  Has a diagnosis of spinal infection tumour or trauma.&#xD;
&#xD;
          -  Requires surgery at more than two (2) levels.&#xD;
&#xD;
          -  Has osteoporosis (excluding osteopenia) as evidenced on plain X-rays, CT scans (or&#xD;
             DEXA scan in cases of doubt).&#xD;
&#xD;
          -  Is pregnant.&#xD;
&#xD;
          -  Is an alcohol and/or drug abuser as defined by currently undergoing treatment for&#xD;
             alcohol and/or drug abuse.&#xD;
&#xD;
          -  Has received drugs that may interfere with bone metabolism within two weeks prior to&#xD;
             the planned surgery date (e.g., steroids or methotrexate) excluding routine&#xD;
             perioperative, non-steroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Has a history of autoimmune disease.&#xD;
&#xD;
          -  Has a history of exposure to injectable collagen implants.&#xD;
&#xD;
          -  Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or&#xD;
             gamma globulins) or collagen.&#xD;
&#xD;
          -  Has received treatment with an investigational therapy (device and/or pharmaceutical)&#xD;
             within 30 days prior to surgery or such treatment is planned during the 24 months&#xD;
             following surgery.&#xD;
&#xD;
          -  Has received any previous exposure to any/all BMPs of either human or animal&#xD;
             extraction.&#xD;
&#xD;
          -  Has a history of allergy to bovine products or a history of general anaphylaxis.&#xD;
&#xD;
          -  Has a history of any endocrine or metabolic disorder known to affect osteogenesis&#xD;
             (e.g., Paget's disease, renal oseodystrophy, Ehlos-Danlos syndrome or osteogenesis&#xD;
             imperfecta).&#xD;
&#xD;
          -  Has any disease that would preclude accurate clinical evaluation (e.g., neuromuscular&#xD;
             disease, etc.).&#xD;
&#xD;
          -  Has a primary diagnosis of a spinal disorder other than degenerative disc disease or&#xD;
             other conditions as set out in &quot;inclusions&quot; above at the involved level(s).&#xD;
&#xD;
          -  Has a condition that requires postoperative medications that interfere with fusion,&#xD;
             such as steroids or prolonged use of non-steroidal anti-inflammatory drugs, excluding&#xD;
             routine perioperative non-steroidal anti-inflammatory drugs. This does not include low&#xD;
             dose aspirin for prophylactic anticoagulation.&#xD;
&#xD;
          -  Has overt or active bacterial infection, local or systemic, and/or a potential for&#xD;
             bacteremia.&#xD;
&#xD;
          -  Has presence of active malignancy or prior history of malignancy (except for basal&#xD;
             cell carcinoma of the skin).&#xD;
&#xD;
          -  Has a documented metal allergy or intolerance to titanium alloy or&#xD;
             cobalt-chrome-molybdenum alloy.&#xD;
&#xD;
          -  Is, in the opinion of the Principal Investigator or Co-Investigators, intellectually&#xD;
             unable to co-operate with the study.&#xD;
&#xD;
          -  Has chronic or acute renal and/or hepatic failure or prior history of renal or hepatic&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huub Kreuwel, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Director, Medical Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moloney &amp; Associates</name>
      <address>
        <city>Wollongong</city>
        <zip>NSW 2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinik</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actifuse</keyword>
  <keyword>INFUSE</keyword>
  <keyword>InductOs</keyword>
  <keyword>DDD</keyword>
  <keyword>degenerative disk disease</keyword>
  <keyword>PLIF</keyword>
  <keyword>PITF</keyword>
  <keyword>PLF</keyword>
  <keyword>poterolateral lumber fusion</keyword>
  <keyword>Bone substitute</keyword>
  <keyword>bone graft</keyword>
  <keyword>synthetic bone substitute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

